Dangers of rosuvastatin identified before and after FDA approval.
Wolfe
Sidney M
SM
D017277:Drug Approval; D005464:Fluorobenzenes / Q000009:adverse effects*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D009135:Muscular Diseases / Q000139:chemically induced; D011743:Pyrimidines / Q000009:adverse effects*; D051437:Renal Insufficiency / Q000139:chemically induced; D012206:Rhabdomyolysis / Q000139:chemically induced; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium